ACADIA Pharmaceuticals Financials - Benzinga

ACADIA Pharmaceuticals Inc

ACADNASDAQ

Trade with Public

Trade with Public

$21.23

-0.95-4.28%

最終更新: Sep 25, 10:34 AM

PRO

なぜ動いているのか？:Acadia Pharma shares are trading lower after the company announced remlifan...

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

ACADIA Pharmaceuticals Financials

ACADIA Pharmaceuticals (ACAD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est

ACADIA Pharmaceuticals (NASDAQ:ACAD) raises FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.240 billion-$1.300 billion vs $1.242 billion estimate.

Benzinga Newsdesk

PRO
ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.07 by 157.14 percent. This is a 12.5 percent increase over earnings of $0.16 per share

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
ACADIA Pharmaceuticals Affirms FY2026 Sales Guidance of $1.220B-$1.280B vs $1.247B Est

ACADIA Pharmaceuticals (NASDAQ:ACAD) affirms FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.220 billion-$1.280 billion vs $1.247 billion estimate.

Benzinga Newsdesk

PRO
ACADIA Pharmaceuticals Q1 EPS $0.02 Misses $0.05 Estimate, Sales $268.062M Miss $280.710M Estimate

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.05 by 60 percent. This is a 81.82 percent decrease over earnings of $0.11 per share

Benzinga Newsdesk

PRO
ACADIA Pharmaceuticals Sees FY2026 Sales $1.220B-$1.280B vs $1.203B Est

ACADIA Pharmaceuticals (NASDAQ:ACAD) sees FY2026 sales of $1.220 billion-$1.280 billion vs $1.203 billion analyst estimate.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved